We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Titan Pharmaceuticals announced Kate DeVarney, Ph.D., Executive Vice President and Chief Scientific Officer, has been elected to the Company's Board of Directors.
The Hollywood movie The Titan in 2018 shows us an upcoming future where the population and pollution continue to grow to a critical point, and most parts in the world including the U.S. have become uninhabitable to humans.
Titan has entered into an amendment of the previously announced definitive asset purchase, supply and support agreement with L. Molteni & C. dei F.lli Alitti Società di Esercizio through which Molteni acquired the European intellectual property related to
Titan Pharmaceuticals has been cleared to start the second phase of a trial of its ropinirole implant for Parkinson’s disease—but will have to postpone it because of financial constraints.